Irvine, CA, June 02, 2026 (GLOBE NEWSWIRE) — IRVINE, CA (March 24, 2026) — Abstrax, a botanical flavor science company transforming how breweries and beverage brands source and use flavor ingredients, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, ranking #5 in the Manufacturing category. This year’s list shines a spotlight on businesses shaping industry and culture through their innovations. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions.

“This recognition reflects what our team has been building from the ground up — a smarter, more efficient way to deliver flavor and aroma to the beverage world,” said Kevin Koby, CEO of Abstrax. “We set out to solve a real problem: the fragility, waste, and inequity baked into traditional agricultural ingredients. What we’ve built isn’t just a better product, it’s a new model for how the industry can operate. Being recognized by Fast Company alongside some of the most innovative companies in the world tells us we’re on the right track, and it energizes us to push even further.”

Over the past 18 months, Abstrax has fundamentally advanced flavor science for the brewing and beverage industry. The company’s proprietary Quantum extraction technology delivers the flavor and aroma impact of one pound of hops using just one ounce of extract, requiring significantly less raw material per batch and reducing the volume of product that must be packaged and shipped. Abstrax also launched a Whole Foods-compliant emulsion system, enabling breweries and beverage brands to meet stringent clean-label standards while achieving the consistency and stability of modern retail demands.

Abstrax further cemented its position as a scientific authority in flavor innovation by expanding its lab with gas chromatography-olfactory (GCO) instrumentation and publishing its first industry white paper, demonstrating how Quantum extracts eliminate harmful sulfur compounds responsible for off-flavors in beer. These advances are backed by real commercial momentum. Through September 2025, Abstrax grew revenue nearly 3x year-over-year to $3.77 million, achieved SQF certification with a Good score, and added marquee brewery partners to its customer roster. Beyond products, the company hosts the annual Skunkworks Lounge competition at the Craft Brewers Conference, drawing thousands of attendees and makes their dosing guides available for free to the public.

The World’s Most Innovative Companies is Fast Company’s hallmark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company’s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.

“Our list of the Most Innovative Companies is about spotlighting organizations that don’t just adapt to change — they drive it,” said Brendan Vaughan, editor-in-chief of Fast Company. “The companies we honor this year are redefining what leadership looks like in 2026, pairing bold ideas with measurable impact and turning breakthrough innovation into real-world value. They are setting the pace for their industries and offering a blueprint for what sustained innovation can achieve.”

The full list of Fast Company’s Most Innovative Companies honorees can now be found at fastcompany.com and on newsstands nation-wide. 

Fast Company hosts the Most Innovative Companies Summit and Gala for honorees on May 19 in New York City. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation.

###

About Abstrax:

Abstrax is a botanical flavor science company and flavor house founded in California. Its research spans terpene chemistry, sensory science, and flavor development across functional beverages, cannabis, and craft brewing. 

Abstrax serves traditional beverage operators directly through AbstraxFlavors.com, bringing a deeper flavor library, botanical expertise, and hands-on formulation support to brands building RTDs, non-alcoholic beverages, specialty sodas, and more. 

Two specialized divisions extend that same science into adjacent markets: Abstrax Tech serves the cannabis industry with terpene blends and peer-reviewed flavor research; Abstrax Hops brings varietal-specific hop flavors and advanced brewing solutions to craft producers. 

Learn more at AbstraxFlavors.com, AbstraxTech.com, and AbstraxHops.com.

About Fast Company:

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit fastcompany.com.

Attachment

• Abstrax Makes it to Fast Company’s Most Innovative Companies 2026

The post Abstrax Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 appeared first on Crypto Insider.

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) — Kantiv, formerly Joist AI, has rebranded its proposal and business development platform built specifically for AEC marketers, expanding its pursuit intelligence offerings to bring firms strategic insights built on their proposal data. Founded in 2022 as Joist AI, the Kantiv rebrand reflects decades of industry expertise from its founding team, four years of learning alongside more than 200 AEC clients, including 1 in 5 of the ENR Top 50 design firms, and a conviction that AEC marketers deserve more than faster proposals.

The platform is agentic and works by going beyond database operations, churning out faster proposals, file-organization, and storage, and adding an intelligence layer for AEC marketers to develop better proposals that learn from each win or loss. From the very first upload, the platform extracts the firm’s tone, project descriptions, images, client history, and resumes, then organizes, reconciles, and labels the data automatically to ensure data hygiene without manual effort. Data is sorted by project, personnel, client, and sector, with additional options available, bringing both high-level and detailed visibility. Marketing teams can then find critical information by content, topic, or a need tied to an RFP rather than file name, analyze incoming RFPs, generate first drafts grounded in the firm’s prior successes and expertise, and run compliance checks before submission.

Moreover, the platform understands the ins-and-outs of AEC-specific RFPs, and is particularly designed for AEC use cases. Rather than relying on a single model, Kantiv is built for multi-LLM orchestration, routing each task to the best-suited model so customers get the highest-quality output and avoid the default responses, lags, or outages that come from depending on one system. This diversified foundation ensures Kantiv customers receive an interruption-free experience, enabling the company to serve enterprise-level clients like those in the ENR Top 50.

Over time, the platform builds a record of a firm’s pursuit history. Marketing leaders can use it to inform go/no-go decisions, identify which markets the firm is winning in, track where project experience is aging, and spot patterns in past wins and losses. The intelligence layer provides automated data governance, natural language processing, predictive analytics, and contextual grounding through an AEC lens. Ultimately, Kantiv allows AEC marketers to tie themselves to data and surface years of institutional knowledge.

“AEC marketers are among the most talented, most overlooked teams in the industry. We started this company to change that,” said Rohan Jawali, CEO and Co-Founder of Kantiv. “When pursuit teams can access everything their firm knows, they spend less time searching and more time winning. And when marketers get that time back, they can reach further to see around corners and pursue the right work with real strategy.”

“For marketers with deep institutional knowledge and an ever-growing inbox, this is like a second brain that you can share with your whole organization,” shared Joey Sminchak, Communications Manager at Horner & Shifrin Inc and Joist AI, now Kantiv, customer. “Not only is the platform a space to store your information, it’s the key to unlocking that information and improving your win strategy.”

The rebrand reflects a change in how the company defines its category. Since launching as Joist AI in 2022, the company has extended the platform’s scope beyond proposal generation into pursuit analytics and business development decision-making. The new name is intended to reflect what the platform delivers rather than how it is built. Kantiv remains an AI-native company but has moved away from AI as a brand identifier, noting that AI capabilities have become standard across the software industry, while AI data intelligence has not. As the industry evolves, data intelligence is emerging as a core competency for AEC marketing leaders.

The name Kantiv is derived from the cantilever, a structural form in which a beam extends into open space, carried by the strength of its anchored base rather than by anything beneath its reach.Co-founder and CEO Rohan Jawali, a former Hensel Phelps engineer, chose the name to reflect the platform’s premise: that a firm’s accumulated institutional knowledge, proposals, and client history can serve as the foundation from which its marketing team extends further into new markets and project types.

Along with a logo change, inspired by the right angles of a cantilever, the company is moving its domain from joist.ai to kantiv.com.

About Kantiv
Kantiv builds pursuit intelligence for Architecture, Engineering, and Construction (AEC) marketing and business development teams. The platform connects a firm’s institutional knowledge, proposals, project data, and client history into an intelligent system that works at every stage of the pursuit lifecycle. Founded by people who came up through AEC marketing and know firsthand what it costs when a talented team spends its best hours on a scramble instead of a strategy, Kantiv exists to give AEC marketers the foundation they need to win the right work and earn their seat at the table. Founded in 2022, the company is headquartered in San Diego, California. For more information, visit kantiv.com.

Media Contact:
Morgan Van Rhee
Senior Account Executive
The MicDrop Agency
morgan@themicdropagency.com 

The post Joist AI Rebrands to Kantiv, Bringing Pursuit Intelligence to AEC Marketing Teams appeared first on Crypto Insider.

MCLEAN, Va., June 01, 2026 (GLOBE NEWSWIRE) — To kick off a month-long celebration of the 15-year anniversary of its founding, the Thought Leadership & Innovation Foundation (TLI) today announced the release of its new whitepaper, The Medicare Advantage Final Rule: A Defining Moment for O&P—and Why Data Will Decide Who Wins, alongside the pilot launch of the Limb Outcomes Voice (LOV), a new patient-centered outcomes platform designed to elevate the voice of individuals living with limb loss and limb difference.

Together, these initiatives represent a coordinated effort to help the orthotics and prosthetics (O&P) industry prepare for the accelerating shift toward value-based healthcare and outcomes-driven reimbursement.

The newly released whitepaper examines how the CMS Medicare Advantage Final Rule signals a broader transformation in healthcare policy—one that increasingly ties reimbursement, network participation, and provider value to measurable clinical outcomes and patient impact.

“The industry is entering a new environment where value can no longer simply be described—it must be demonstrated,” said Bill Oldham, Founder of the Thought Leadership & Innovation Foundation. “Outcomes data and patient-reported experiences are becoming essential infrastructure for the future of O&P.”

Central to the whitepaper is the growing importance of the Limb Loss and Preservation Registry (LLPR), which enables providers and researchers to systematically capture longitudinal outcomes data across the limb loss and limb preservation population.

At the same time, TLI is launching the pilot phase of Limb Outcomes Voice (LOV), a patient engagement and reporting platform designed to give individuals living with limb loss and limb difference direct access to meaningful insights about their mobility, function, quality of life, and health outcomes.

LOV allows participants to:

• Complete outcomes surveys and assessments
• View personalized reports and benchmark insights
• Access educational resources and support organizations
• Contribute their voice to a larger national outcomes effort

According to TLI, the connection between the CMS Final Rule, LLPR, and LOV is intentional.

“The future of healthcare will increasingly be shaped by real-world outcomes and patient experience,” Oldham said. “LOV helps ensure that the patient voice becomes part of the data infrastructure informing clinical care, policy decisions, and reimbursement models.”

The organization believes the combination of provider-driven registry data through LLPR and patient-reported insights through LOV creates a more complete picture of outcomes across the O&P continuum of care.

The whitepaper calls on O&P providers, manufacturers, researchers, and advocacy organizations to work collaboratively to strengthen outcomes measurement, improve data transparency, and ensure the profession plays an active role in defining how value is measured in the future healthcare landscape.

About the Thought Leadership & Innovation Foundation

The Thought Leadership & Innovation Foundation (TLI) is a nonprofit organization focused on advancing innovation, collaboration, and data-driven transformation across healthcare and rehabilitation. Through strategic initiatives, research partnerships, and technology-enabled platforms, TLI works to improve patient outcomes and strengthen the future of care for individuals living with limb loss and limb difference.

For more information, visit:
www.thoughtfoundation.org

Media Contact:
Thought Leadership & Innovation Foundation
info@thoughtfoundation.org

The post Thought Leadership & Innovation Foundation Releases Whitepaper on CMS Medicare Advantage Final Rule and Announces Pilot Launch of Limb Outcomes Voice (LOV) appeared first on Crypto Insider.

London, UK, June 01, 2026 (GLOBE NEWSWIRE) — LED Mirror World UK today announced the release of its 2026 Industry Report on Bathroom Mirror Trends, examining emerging consumer preferences across the UK bathroom renovation market. The report highlights growing interest in smart bathroom technology, integrated lighting solutions, certified safety standards, and contemporary mirror designs as homeowners continue investing in modern bathroom upgrades.

LED Mirror World UK provides premium LED bathroom mirrors and smart illuminated mirror solutions designed for modern residential bathrooms.

As homeowners increasingly invest in bathroom upgrades that blend aesthetics with functionality, LED Mirror World UK is positioning itself as a trusted destination for contemporary mirror solutions designed to meet the expectations of modern households. The company’s extensive collection includes illuminated mirrors, smart technology-enabled designs, and decorative options suited to a variety of bathroom styles.

A key focus of the company’s offering is its premium LED bathroom mirror collection, which provides customers with a combination of stylish design, practical lighting, and everyday usability. The collection is designed to support both renovation projects and new bathroom installations while maintaining a strong emphasis on quality and value.

The announcement comes as consumers continue to seek products that offer more than traditional functionality. Bathroom mirrors have become an important design feature in many homes, with customers increasingly looking for products that contribute to both visual appeal and convenience.

Among the retailer’s most popular categories are its bathroom mirrors with lights, which are designed to improve visibility while enhancing the overall atmosphere of a bathroom space. Available in multiple styles and configurations, these illuminated mirrors are intended to support daily routines while complementing modern interior design preferences.

Another area of growing demand is the company’s collection of smart bluetooth bathroom mirror products. These mirrors incorporate smart functionality that aligns with the increasing adoption of connected home technology. By combining integrated lighting with contemporary features, the collection offers customers a practical solution for creating more functional and enjoyable bathroom environments.

“Our goal is to provide customers with bathroom mirror solutions that combine quality craftsmanship, practical features, and attractive design,” said a spokesperson for LED Mirror World UK. “The company continues to expand awareness of products that meet the needs of modern homeowners while remaining accessible and competitively priced.”

The retailer also offers a dedicated selection of round bathroom mirror designs. These products have become increasingly popular due to their versatility and ability to complement a wide range of bathroom aesthetics. Their clean and contemporary appearance makes them a preferred option for homeowners seeking a modern visual focal point.

In addition to decorative options, LED Mirror World UK continues to highlight its collection of backlit bathroom mirror products. These mirrors are designed to provide balanced illumination while creating a sophisticated appearance that works well in both contemporary and classic bathroom settings.

Beyond product design and selection, the company places significant emphasis on customer confidence throughout the purchasing journey. Customers benefit from free and fast shipping across the UK, helping streamline the process of ordering larger bathroom fixtures online. To further enhance peace of mind, LED Mirror World UK also provides free damage replacement should a product experience transit-related issues before delivery.

The company additionally supports its products with a three-year warranty, reflecting its commitment to quality and long-term reliability. Safety remains another important component of the retailer’s offering, with products backed by UKCA and CE certification standards. Many products also feature IP44-rated protection, providing additional reassurance for use within bathroom environments.

“Customer confidence remains central to every aspect of the business,” the spokesperson added. “From product quality and safety certifications to delivery support and after-sales service, LED Mirror World UK remains focused on creating a dependable shopping experience for customers throughout the UK.”

As bathroom design trends continue to evolve, LED Mirror World UK believes homeowners will continue prioritising products that combine visual appeal, smart functionality, and long-term reliability. Through its growing collection of illuminated mirrors, connected technology solutions, and customer-focused service policies, the company aims to remain a trusted resource for consumers seeking modern bathroom mirror solutions.

About LED Mirror World UK

LED Mirror World UK is an online retailer serving customers throughout the United Kingdom with a range of LED bathroom mirrors and illuminated mirror solutions. The company specializes in modern mirror designs that combine contemporary styling, smart functionality, and practical everyday performance. Its product range includes bluetooth bathroom mirrors, backlit mirrors, illuminated mirrors, and other bathroom-focused mirror designs supported by customer-first service policies.

Press Inquiries

PR Relations Team
help [at] ledmirrorworld.co.uk
https://ledmirrorworld.co.uk/
London, UK

The post LED Mirror World UK Releases 2026 Industry Report Highlighting Growing Demand for Smart Bathroom Mirrors in the UK appeared first on Crypto Insider.

BEIJING, May 31, 2026 (GLOBE NEWSWIRE) — This year marks the 70th anniversary of China-Africa relations. CGTN has published an article highlighting Africa’s priority role in China’s overall foreign policy, while tracing how the China-Africa partnership has been forged and strengthened over decades. The article also explores how deepening cooperation in recent years has helped enhance the voice and representation of the Global South, and contributed to advancing a more balanced and democratic international order.

As Chinese President Xi Jinping and Egyptian President Abdel-Fattah al-Sisi exchanged congratulatory messages on Saturday to mark the 70th anniversary of China-Egypt ties, the occasion also highlighted a broader milestone: seven decades of China-Africa relations.

Xi noted that over the past 70 years, China-Egypt relations have become a model of amity, solidarity and cooperation among developing countries, as well as a benchmark for cooperation between China and Arab states and between China and Africa.

Today, China-Africa relations have evolved from a friendship forged in shared struggles into a dynamic partnership dedicated to development, modernization and the rise of the Global South.

From solidarity to strategic partnership

The foundations of China-Africa friendship were laid during a period of profound political change.

From the 1950s to the 1970s, China firmly supported African countries in their struggles for national independence and liberation. African nations, in turn, played a decisive role in restoring the lawful seat of the People’s Republic of China at the United Nations in 1971. Of the 76 votes cast in favor of the resolution, 26 came from African countries – laying a strong foundation for China-Africa mutual trust.

Earlier this year, Chinese Foreign Minister Wang Yi visited Africa, continuing a 36-year tradition of making the continent the destination of China’s foreign minister’s first overseas trip each year, highlighting the importance of China-Africa relations.

Over the past two decades, China-Africa cooperation has expanded rapidly. The establishment of the Forum on China-Africa Cooperation (FOCAC) in 2000 provided an institutional framework for cooperation, while China’s Africa policy of sincerity, real results, amity and good faith further guided bilateral relations. In 2015, the two sides elevated their ties to a comprehensive strategic cooperative partnership and launched the “Ten Cooperation Plans,” setting a strong foundation for rapid modernization across the African continent.

At the 2024 FOCAC summit, China and Africa further upgraded their relationship to an all-weather community with a shared future for the new era. China also expanded duty-free access from 33 African countries to all 53 African countries with diplomatic ties by 2025, becoming the first major economy to grant unilateral zero-tariff treatment across all product categories to every African country with which it has diplomatic relations.

Humphrey Moshi, a prominent Tanzanian economist, described China-Africa cooperation as a significant example of Global South solidarity. He said such solidarity helps transform developing countries from “passive participants” into “active shapers” of international rules.

Advancing modernization through practical cooperation

While political trust forms the foundation of China-Africa relations, economic cooperation has become both the stabilizer and growth engine of the partnership.

According to data released by China’s General Administration of Customs, China-Africa trade reached a record $348 billion in 2025, up 17.7% from the previous year, with China remaining Africa’s largest trading partner for the 17th consecutive year. The momentum has continued into 2026. In the first quarter alone, China’s trade with the African countries totaled 646.56 billion yuan ($92.2 billion), a year-on-year increase of 23.7%.

At the same time, the Belt and Road Initiative has reshaped connectivity across the continent by upgrading the railway system with projects such as the Tazara Railway and the Mombasa-Nairobi Standard Gauge Railway, which are flagship projects that set examples for high-quality Belt and Road cooperation between China and Africa.

According to China’s Foreign Ministry, China has signed debt-relief agreements or reached debt-relief understandings with 19 African countries as of 2023, making it the largest contributor to debt-service suspension efforts under the G20 framework.

Meanwhile, China has trained tens of thousands of African professionals through scholarships, vocational training and educational exchange programs. As of June 2025, China has established 17 Luban Workshops across 15 African countries, while the China-Africa university cooperation plan, a higher education initiative pairing Chinese universities with African institutions, has connected 114 higher education institutions.

Paul Frimpong, executive director and senior research fellow of the Africa-China Centre for Policy & Advisory, said China’s contribution to Africa’s development is increasingly visible.

“China’s sharing of knowledge, skills and experience in sectors such as manufacturing and green energy is having a profound impact on Africa’s journey toward modernization and self-reliance,” he added.

https://news.cgtn.com/news/2026-05-30/China-Africa-ties-at-70-Path-to-a-shared-dream-of-modernization-1NzbT7rDWhy/p.html

The post CGTN: China-Africa ties at 70: From shared struggles to a common dream of modernization appeared first on Crypto Insider.

NEW YORK, May 31, 2026 (GLOBE NEWSWIRE) — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against POET Technologies Inc. (NASDAQ: POET) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired POET Technologies Inc. securities between April 1, 2026 and April 27, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/POET.

POET Technologies Inc. Case Details

The Complaint alleges that the Defendants made false and/or misleading statements and/or failed to disclose that:

(1)   POET misrepresented its tax status due to it likely being deemed a passive foreign investment company (or “PFIC”) under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders;
(2)   the foregoing tax issue would, if discovered, make POET a less attractive investment than it would otherwise be, thus threatening POET’s valuation;
(3)   Defendant Thomas Mika, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET’s business agreements in a public interview, thus endangering POET’s business prospects, and
(4)   as a result, Defendants’ statements about POET’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What’s Next for POET Technologies Inc. Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/POET. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in POET Technologies Inc. you have until June 29, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to POET Technologies Inc. Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for POET Technologies Inc. Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.
Prior results do not guarantee similar outcomes.

The post Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm appeared first on Crypto Insider.

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –

– In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio –

– Lorundrostat demonstrated a favorable safety profile in participants with and without chronic kidney disease over 12 weeks –

RADNOR, Pa., May 30, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today presented new clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) in Gdańsk, Poland.

“Despite the availability of current therapies, up to 75 percent of patients with chronic kidney disease still have uncontrolled or resistant blood pressure, contributing to a high risk of cardiovascular events and kidney disease progression,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “These results, together with our Explore-CKD trial findings, demonstrate lorundrostat’s potential to address the compounded burden of hypertension and CKD, underscoring its promise as an important potential treatment option for this difficult-to-treat population with high unmet need.”

The analysis evaluated the efficacy and safety of once-daily lorundrostat 50 mg by CKD status among 800 participants with uncontrolled or resistant hypertension enrolled in the randomized, double-blind, placebo-controlled Phase 3 Launch-HTN trial. Among participants with CKD (n=192), 71% were receiving three or more anti-hypertensive medications at baseline, compared with 56% of those without CKD. In addition, 31% of participants with CKD had systolic blood pressure (SBP) ≥160 mmHg at baseline, versus 17% of participants without CKD.

Lorundrostat demonstrated significant reductions in SBP that were comparable between CKD and non-CKD participants. At week 12, placebo-adjusted SBP reductions were 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). A greater proportion of lorundrostat-treated participants also achieved target SBP of <130 mmHg at week 12 compared with placebo, both among CKD participants (44% vs 18%) and non-CKD participants (48% vs 22%).

Lorundrostat treatment was also associated with a significant placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among 84 participants with CKD and baseline albuminuria, achieving a 52.2% placebo-adjusted reduction at 12 weeks (p<0.0001). Lorundrostat had a favorable safety profile in both CKD and non-CKD participants with low rates of confirmed hyperkalemia, 2.4% and 0% respectively.

“These findings are compelling because they show that lorundrostat achieves comparable blood pressure reductions regardless of kidney disease status, while also significantly reducing albuminuria, a key marker of kidney injury and disease progression, in these patients,” said Dr. Liffert Vogt, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam. “Aldosterone is a key driver of both chronic kidney disease and difficult-to-treat hypertension, and these findings demonstrate the potential for lorundrostat to provide needed cardiorenal protection for these patients.”

Previous data from the Explore-CKD trial, presented at ASN Kidney Week 2025, showed that adding lorundrostat to standard-of-care therapy reduced both blood pressure and albuminuria in participants with hypertension and CKD. Across both the Launch-HTN and Explore-CKD trials, lorundrostat demonstrated clinically meaningful blood pressure reductions in participants with hypertension, including those in high-risk populations with CKD, obesity and Black or African American participants.

Lorundrostat is currently under review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

About Launch-HTN 
Launch-HTN (NCT06153693) was a global, randomized Phase 3 double-blind, placebo-controlled trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: placebo; lorundrostat 50 mg once daily; or lorundrostat 50 mg once daily with the option to increase to 100 mg at week six. The primary endpoint was change from baseline in SBP at 6 weeks versus placebo, measured by automated office blood pressure monitoring.

About Chronic Kidney Disease (CKD)
CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 1 in 10 of adults aged 18 or older (37 million people) are estimated to have CKD. Approximately 21% of adults with high blood pressure are estimated to have CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure (BP) control. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to both uncontrolled BP and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Hypertension
Having sustained, elevated blood pressure (BP) (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat
Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as CKD, OSA and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

Mineralys has now completed six late-stage clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was generally well tolerated in both trials with a favorable safety profile.

About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the anticipated timing of the U.S. Food and Drug Administration’s (FDA) review of our accepted New Drug Application (NDA) and any subsequent regulatory approval of lorundrostat; and the planned future clinical development of lorundrostat and the timing thereof. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; any delays in the FDA’s review of our accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of our NDA submission; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Tanabe Pharma Corporation to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

The post Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) appeared first on Crypto Insider.

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SES AI Corporation (NYSE: SES) between January 29, 2025 and March 4, 2026, both dates inclusive (the “Class Period”), of the important June 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased SES AI securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SES AI class action, go to https://rosenlegal.com/submit-form/?case_id=56471 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) SES AI overstated its business prospects by materially overstating the expected results that could be achieved by deals with companies that have limited or no operations; (2) SES AI created an appearance of revenue by purchasing services in exchange for purchases of Molecular Universe; (3) contrary to its positive statements regarding growth prospects, SES AI was affected by material logistics constraints in the fourth quarter of 2025 which would materially affect Q4 2025 revenues; (4) the foregoing called into question SES AI’s growth prospects for 2026, which were confirmed due to lower-than expected 2026 revenue guidance; and (5) as a result, defendants’ statements about SES AI’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SES AI class action, go to https://rosenlegal.com/submit-form/?case_id=56471 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

The post SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES appeared first on Crypto Insider.

ALBANY, N.Y., May 29, 2026 (GLOBE NEWSWIRE) — The New York State Builders Association (NYSBA) today applauded Governor Kathy Hochul and the New York State Legislature for enacting transformational reforms to the State Environmental Quality Review Act (SEQRA) as part of the 2026-2027 State Budget, signed into law today by the Governor.

The reforms represent one of the most significant changes to New York’s environmental review process in decades and mark a major step forward in streamlining housing production, accelerating economic development, and addressing New York’s ongoing affordability crisis.

After months of intensive negotiations and collaboration among stakeholders, the final legislation delivers long-overdue changes that will help remove unnecessary barriers to housing creation, encourage smart growth and investment, and make it easier to build the homes New Yorkers desperately need.

“Governor Hochul demonstrated the kind of pragmatic, results-driven leadership New York desperately needed by bringing together stakeholders and securing one of the most consequential SEQRA reforms in generations,” said Bruno Schickel, President of the New York State Builders Association. “The Governor not only achieved the transformational reforms she fought for, but delivered meaningful changes that will help streamline housing production, spur economic development, and address New York’s growing affordability crisis. These long-overdue reforms will create new opportunities for working families, support responsible growth, and help move critically needed housing projects forward across the State.”

NYSBA also thanked Senate Majority Leader Andrea Stewart-Cousins, Assembly Speaker Carl Heastie, and members of the State Legislature for their leadership and partnership in advancing the legislation.

“This is a tremendous victory for housing, for economic opportunity, and for the future of New York,” Schickel added. “Congratulations to Governor Hochul and everyone involved in making this historic achievement possible.”

The New York State Builders Association has long advocated for balanced and effective SEQRA reforms that protect the environment while ensuring New York can meet its pressing housing and economic development needs.

FOR MORE INFORMATION, PLEASE CONTACT:
New York State Builders Association
Email: info@nysba.com | Phone: 518-465-2492

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e027f0e7-800f-4a06-9706-6bdc454bd1fc

The post New York State Builders Association Applauds Governor Hochul and State Legislature for Historic SEQRA Reforms appeared first on Crypto Insider.

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Globant S.A. (NYSE: GLOB) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Globant securities between February 15, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/GLOB.

Globant Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

1. Globant’s touted “Latin American pivot” was not successful and the Company’s Latin American operations were experiencing declining demand, client defections, and project cancellations; 
2. contrary to Defendants’ claims that Globant was a market leader and employer of choice in the region, the Company froze employee wages in Mexico and Argentina, triggering widespread employee turmoil and degrading client services; and 
3. as a result of the foregoing, Defendants’ positive statements regarding Globant’s business, operations, and prospects in Latin America were materially misleading.
   

What’s Next for Globant Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/GLOB. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Globant you have until June 23, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Globant Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Globant Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.
Prior results do not guarantee similar outcomes.

The post Bronstein, Gewirtz & Grossman LLC Urges Globant S.A. Investors to Act: Class Action Filed Alleging Investor Harm appeared first on Crypto Insider.